News

Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome

September 25, 2017

REDWOOD CITY, Calif. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical ...

Read More

Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome

September 15, 2017

Updated Data Highlighted in Poster Presentation at 10 th International Meeting of Pediatric Endocrinology Phase III ...

Read More

Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome

September 13, 2017

Protection of Associated Claims into 2035 REDWOOD CITY, Calif. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (...

Read More
Soleno – Home